Objective To evaluate the effectiveness and safety of an ultra-lowcost uterine balloon tamponade package (ESM-UBTTM) for facility-based management of uncontrolled postpartum haemorrhage (PPH) in Kenya, Sierra Leone, Senegal, and Nepal.Design Prospective multi-centre case series.Setting Facilities in resource-scarce areas of Kenya, Sierra Leone, Nepal, and Senegal.Population Women with uncontrolled postpartum haemorrhage in 307 facilities across the four countries.Methods A standardised ESM-UBT package was implemented in 307 facilities over 29 months (1 September 2012 to 1 February 2015. Data were collected via a multi-pronged approach including data card completion, chart reviews, and provider interviews. Beginning in August 2014, women who had previously undergone UBT placement were sought and queried regarding potential complications associated with UBT use.Main outcome measures All-cause survival, survival from PPH, and post-UBT use complications (surgery, hospitalisation, antibiotics for pelvic infection) associated with UBT use.Results 201 UBTs were placed for uncontrolled vaginal haemorrhage refractory to all other interventions. In all, 38% (71/ 188) of women were either unconscious or confused at the time of UBT insertion. All-cause survival was 95% (190/201). However, 98% (160/163) of women survived uncontrolled PPH if delivery occurred at an ESM-UBT online facility. One (1/151) potential UBT-associated complication (postpartum endometritis) was identified and two improvised UBTs were placed in women with a ruptured uterus.Conclusions These pilot data suggest that the ESM-UBT package is a clinically promising and safe method to arrest uncontrolled postpartum haemorrhage and save women's lives. The UBT was successfully placed by all levels of facility-based providers. Future studies are needed to further evaluate the effectiveness of ESM-UBT in low-resource settings.Keywords Maternal mortality, postpartum haemorrhage, uterine balloon tamponade. Please cite this paper as: Burke TF, Ahn R, Nelson BD, Hines R, Kamara J, Oguttu M, Dulo L, Achieng E, Achieng B, Natarajan A, Maua J, Kargbo SAS, Altawil Z, Tester K, de Redon E, Niang M, Abdalla K, Eckardt MJ. A postpartum haemorrhage package with condom uterine balloon tamponade: a prospective multi-centre case series in Kenya, Sierra Leone, Senegal, and Nepal. BJOG 2016;123:1532-1540

Uterine rupture is a public health problem in developing countries. When it is spontaneous, it occurs most often during labor in a context of scarred uterus. Uterine rupture during pregnancy is a rare situation. The diagnosis is not always obvious and morbidity and maternal and fetal mortality is still high. We report a case of spontaneous uterine rupture during pregnancy at 35 weeks of an unscarred uterus before labour. This is an exceptional case that we observe for the first time in our unit.

No abstract

No abstract

Objective To determine the risk of recurrent trophoblastic disease after normalisation of human chorionic gonadotrophin (hCG) levels in women with hydatidiform mole.Design A retrospective review of data from a national gestational trophoblastic disease centre.Setting The Trophoblastic Disease Unit, Dakar, Senegal.Sample Women with pregnancies affected by hydatidiform mole registered between 2006 and 2012.Methods The women were followed up in accordance with the hospital protocol 'Score de Dakar'. For women who progressed to gestational trophoblastic neoplasia (GTN) the time to onset of GTN, treatment and evolution were evaluated. The rate of evolution to GTN after normalisation of hCG was determined.Main outcome measures Rate of occurrence of GTN after chemotherapy for hydatidiform mole.Results Five hundred and thirty-one women were diagnosed to have molar pregnancies. According to the hospital's protocol, 107 (20.2%) of these had chemotherapy and 224 (42.2%) had prophylactic chemotherapy. Five hundred and thirteen women (96.4%; 95% confidence interval [95% CI] 95.05-98.14%) achieved remission. Eighteen women (3.4%; 95% CI 1.86-4.94%) developed GTN (11 before remission and seven after remission). Seven women out of the 18 developed GTN after hCG normalisation (1.3%). Five of these seven were diagnosed beyond the recommended period of follow up. The mean interval to diagnosis of GTN was 18.7 months. These seven women underwent combination chemotherapy: five achieved complete remission whereas two died from GTN.Conclusions Cytotoxic therapy for hydatidiform mole does not prevent GTN, it delays its diagnosis and promotes GTN after normalisation of hCG.

IntroductionLe défi des pays en voie de développement est la disponibilité de méthodes de diagnostic rapide et précis pour le management de la tuberculose. Des techniques moléculaires offrent cet avantage et nous avons utilisé le test GeneXpert MTB/RIF dans le diagnostic de la tuberculose extra-pulmonaire pour évaluer sa performance par rapport aux méthodes conventionnelles.MéthodesEntre 2010 et 2015, 544 échantillons cliniques extra-pulmonaires ont été recueillis et traitées par la microscopie, la culture et le GeneXpert. L'étude de la sensibilité aux antituberculeux a été effectué avec le MGIT 960. Le Génotype MTBDRplus a été utilisé pour confirmer les cas de résistance à la rifampicine détectés par le système GX. RésultatsLa population d'étude de 544 patients incluait 55,15% d'hommes et 44,85% de femmes. L'âge des patients variait entre 1 à 92 avec la majorité dans le groupe d'âge 18-45 ans. La sensibilité et la spécificité globale de la microscopie étaient de 43,86% et 98,36%, et pour le GeneXpert® 94,74% et 97,95% respectivement avec 95% IC. Deux résultats de résistance à la rifampicine discordants ont été trouvées entre le test GeneXpert et la méthode phénotypique. Les résultats du test MTBDRplus ont montré une concordance de 100% avec ceux du MGIT 960 pour les cas discordants de résistance à la rifampicine.ConclusionCette étude a montré que le test GeneXpert a une plus grande sensibilité pour le diagnostic de routine de la tuberculose extra-pulmonaire et devrait être utilisé à la place de la microscopie. Les cas de résistance à la rifampicine détectés par le GeneXpert doivent être confirmés par d'autres tests moléculaires avant d'initier un traitement.

No abstract

No abstract